← Back to Search

Alinity m HR HPV for Human Papillomavirus

N/A
Waitlist Available
Research Sponsored by Abbott Molecular
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights

Study Summary

This trial will be testing two different ways of collecting cervical cancer screening specimens in order to determine which is more effective in detecting disease.

Eligible Conditions
  • Human Papillomavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease Progression greater than or equal to (cervical intraepithelial neoplasia) CIN3
Secondary outcome measures
Disease progression greater than or equal to cervical intraepithelial neoplasia (CIN2)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Alinity m HR HPVExperimental Treatment1 Intervention
The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes [(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)].
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alinity m HR HPV
2021
N/A
~14940

Who is running the clinical trial?

Abbott MolecularLead Sponsor
2 Previous Clinical Trials
264 Total Patients Enrolled

Media Library

Alinity m HR HPV Clinical Trial Eligibility Overview. Trial Name: NCT04746872 — N/A
Human Papillomavirus Research Study Groups: Alinity m HR HPV
Human Papillomavirus Clinical Trial 2023: Alinity m HR HPV Highlights & Side Effects. Trial Name: NCT04746872 — N/A
Alinity m HR HPV 2023 Treatment Timeline for Medical Study. Trial Name: NCT04746872 — N/A
Human Papillomavirus Patient Testimony for trial: Trial Name: NCT04746872 — N/A
~3514 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top